UAMCO Acquires 31.5 Billion Won in Convertible Bonds of Dongsung Pharmaceutical, Raising Dilution Concerns
UAMCO Pharmaceutical Industry No. 1 Corporate Financial Stability Private Investment Fund acquired 31.5 million convertible bonds of Dongsung Pharmaceutical at 1,000 won each, totaling 31.5 billion won.
This increases UAMCO's specific securities ownership ratio from 32.69% to 49.27%, and upon conversion, additional shares will dilute existing shareholders.
The purpose of the CB issuance is not disclosed, but it likely aims to raise funds for financial restructuring or operational needs.
[AI Summary]The massive CB issuance by Dongsung Pharmaceutical raises concerns about shareholder dilution, likely pressuring the stock price in the short term. While UAMCO's increased stake may indicate potential involvement in management, the overhang from convertible bonds remains a risk.
KOSPI Filing Information
Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders
Company: Dongsung Pharmaceutical (002210)
Submission: UAMCO Pharmaceutical Industry No.1 Corporate Financial Stability Private Investment Fund